|
24 Sep 2025 |
Dr. Reddy's Labs
|
Consensus Share Price Target
|
1298.10 |
1285.13 |
- |
-1.00 |
hold
|
|
|
|
|
17 May 2013
|
Dr. Reddy's Labs
|
Chola Wealth Direct
|
1298.10
|
2310.00
|
2077.65
(-37.52%)
|
Target met |
Buy
|
|
|
Background: Dr. Reddy's is a global generic pharmaceutical company with focus on the US, Europe, Russia and India. Finished dosage and API account for a bulk of the revenues, with up to 60% of sales derived from overseas operations. With a strong research pipeline, its R&D; is focused in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infections. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. It has one of the largest ANDA & patent challenge pipelines has strengthened presence through the launch of several niche products....
|
|
30 Apr 2013
|
Dr. Reddy's Labs
|
Ashika Research
|
1298.10
|
2280.00
|
2023.75
(-35.86%)
|
Target met |
Buy
|
|
|
Dr. Reddy's is a vertically integrated company with presence across the pharmaceutical value chain through its core businesses of Global Generics, Pharmaceutical...
|
|
20 Feb 2013
|
Dr. Reddy's Labs
|
Chola Wealth Direct
|
1298.10
|
1930.00
|
1839.95
(-29.45%)
|
Pre-Bonus/
Split |
Neutral
|
|
|
Background: Dr. Reddy's is a global generic pharmaceutical company with focus on the US, Europe, Russia and India. Finished dosage and API account for a bulk of the revenues, with up to 60% of sales derived from overseas operations. With a strong research pipeline, its R&D; is focused in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infections. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. It has one of the largest ANDA & patent challenge pipelines has strengthened presence through the launch of several...
|
|
05 Nov 2012
|
Dr. Reddy's Labs
|
Chola Wealth Direct
|
1298.10
|
1828.00
|
1794.70
(-27.67%)
|
Pre-Bonus/
Split |
Neutral
|
|
|
Background: Dr. Reddy's is a global generic pharmaceutical company with focus on the US, Europe, Russia and India. Finished dosage and API account for a bulk of the revenues, with up to 60% of sales derived from overseas operations. With a strong research pipeline, its R&D; is focused in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infections. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. It has one of the largest ANDA & patent challenge pipelines has strengthened presence through the launch of several...
|
|
03 Feb 2012
|
Dr. Reddy's Labs
|
Ashika Research
|
1298.10
|
1795.00
|
1670.50
(-22.29%)
|
Pre-Bonus/
Split |
Accumulate
|
|
|
company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's...
|